• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    USANA Health Sciences Reports Second Quarter 2024 Results

    7/23/24 4:05:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $USNA alert in real time by email

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal second quarter ended June 29, 2024.

    Key Financial & Operating Results

    • Second quarter net sales were $213 million versus $238 million during Q2 2023.
    • Second quarter diluted EPS was $0.54 as compared with $0.89 during Q2 2023.
    • Company updates fiscal year 2024 net sales and diluted EPS outlook to $850 million to $880 million and $2.40 to $2.55 (previously $850 million to $920 million and $2.40 to $3.00).

    Q2 2024 Financial Performance

    Consolidated Results

    Net Sales

    $213 million

    • -11% vs. Q2 2023

     

     

    • -8% constant currency vs. Q2 2023

     

     

    • -7% sequentially

     

     

    • -6% constant currency sequentially

     

     

    • -$5 million YOY FX impact, or -2%

    Diluted EPS

    $0.54

    • -39% vs. Q2 2023

     

     

    • -37% sequentially

    Active Customers

    468,000

    • -4% vs. Q2 2023

     

     

    • -5% sequentially

    "Second quarter operating results were below our expectations," said Jim Brown, President and Chief Executive Officer.

    "Ongoing macroeconomic pressures in several of our key markets continue to impact consumer spending. This in turn creates challenges in our ability to attract and engage new customers and generate sales momentum. To counter these challenges, we have made several strategic changes in our business over the past few quarters, including (i) restructuring our commercial team, (ii) heightening our focus on product innovation, (iii) increasing our efforts to engage our sales leaders with an Associate-first approach, (iv) expanding into India, and (v) evaluating more business development activities.

    "Next month, we will be hosting our Americas & Europe Convention in Las Vegas, Nevada along with other Associate engagement-focused events in the back half of the year. We are also planning to offer a more robust promotional calendar throughout the remainder of the year."

    Q2 2024 Regional Results:

    Asia Pacific Region

    Net Sales

    $171 million

    • -12% vs. Q2 2023

     

     

    • -9% constant currency vs. Q2 2023

     

     

    • -8% sequentially

     

     

    • 80% of consolidated net sales

    Active Customers

    369,000

    • -4% vs. Q2 2023

     

     

    • -7% sequentially

    Asia Pacific Sub-Regions

    Greater China

    Net Sales

    $116 million

    • -10% vs. Q2 2023

     

     

    • -8% constant currency vs. Q2 2023

     

     

    • -9% sequentially

    Active Customers

    250,000

    • Flat vs. Q2 2023

     

     

    • -9% sequentially

    North Asia

    Net Sales

    $20 million

    • -23% vs. Q2 2023

     

     

    • -19% constant currency vs. Q2 2023

     

     

    • -8% sequentially

    Active Customers

    42,000

    • -18% vs. Q2 2023

     

     

    • -7% sequentially

    Southeast Asia Pacific

    Net Sales

    $35 million

    • -10% vs. Q2 2023

     

     

    • -7% constant currency vs. Q2 2023

     

     

    • -2% sequentially

    Active Customers

    77,000

    • -6% vs. Q2 2023

     

     

    • +1% sequentially

    Americas and Europe Region

    Net Sales

    $42 million

    • -5% vs. Q2 2023

     

     

    • -5% constant currency vs. Q2 2023

     

     

    • -1% sequentially

     

     

    • 20% of consolidated net sales

    Active Customers

    99,000

    • -4% vs. Q2 2023

     

     

    • Flat sequentially

    Balance Sheet and Share Repurchase Activity

    The Company generated $8 million in operating cash flow during second quarter and ended the quarter with $332 million in cash and cash equivalents while remaining debt-free. The Company did not repurchase any shares during the quarter. As of June 29, 2024, the Company had approximately $62 million remaining under the current share repurchase authorization.

    Fiscal Year 2024 Outlook

    The Company is updating its net sales and earnings per share outlook for fiscal year 2024, as follows:

    Fiscal Year 2024 Outlook

     

    Revised Range

    Previous Range

    Consolidated Net Sales

    $850 - $880 million

    $850 - $920 million

    Diluted EPS

    $2.40 - $2.55

    $2.40 - $3.00

    "While we anticipated lower sequential operating results following a successful promotional period in the first quarter, lower than anticipated active customer counts negatively impacted our second quarter results," said Doug Hekking, Chief Financial Officer. "Additionally, the strengthening of the U.S. dollar created downward pressure on both net sales and operating margin during the quarter."

    Mr. Hekking continued, "We are revising our fiscal 2024 outlook to reflect year-to-date operating results, our expectation for a continued challenging operating environment across many of our markets, higher than anticipated unfavorable currency exchange rate impact on operating results, and an increased effective tax rate. We recognize the need to continue investing in strategic initiatives while also aligning costs with sales performance. Our balance sheet remains strong with $332 million of cash, zero debt, and we continue to generate solid cash flow."

    Management Commentary Document and Conference Call

    For further information on the USANA's operating results, please see the Management Commentary document, which has been posted on the Company's website (http://ir.usana.com) under the Investor Relations section. USANA's management team will hold a conference call and webcast to discuss today's announcement with investors on Wednesday, July 24, 2024 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA's website at http://ir.usana.com. The call will consist of brief opening remarks by the Company's management team, followed by a questions and answers session.

    Non-GAAP Financial Measures

    The Company prepares its financial statements using U.S. generally accepted accounting principles ("GAAP"). Constant currency net sales, earnings, EPS and other currency-related financial information (collectively, "Financial Results") are non-GAAP financial measures that remove the impact of fluctuations in foreign-currency exchange rates ("FX") and help facilitate period-to-period comparisons of the Company's Financial Results that we believe provide investors an additional perspective on trends and underlying business results. Constant currency Financial Results are calculated by translating the current period's Financial Results at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount to the prior-year period's Financial Results.

    About USANA

    USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, Italy, and India. More information on USANA can be found at www.usana.com.

    Safe Harbor

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including: global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Associates; risk associated with governmental regulation of our products, manufacturing and direct selling business model in the United States, China and other key markets; potential negative effects of deteriorating foreign and/or trade relations between or among the United States, China and other key markets; potential negative effects from geopolitical relations and conflicts around the world, including the Russia-Ukraine conflict and the conflict in Israel; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; adverse publicity risks globally; risks associated with commencing operations in India and future international expansion and operations; uncertainty relating to the fluctuation in U.S. and other international currencies; and the potential for a resurgence of COVID-19, or another pandemic, in any of our markets in the future and any related impact on consumer health, domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company's expectations, except as required by law.

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except per share data)

    (unaudited)

     

     

    Quarter Ended

     

    June 29,

    2024

    July 1,

    2023

    Net sales

    $

    212,869

     

    $

    238,202

     

    Cost of sales

     

    40,333

     

     

    43,326

     

    Gross profit

     

    172,536

     

     

    194,876

     

    Operating expenses:

     

     

    Associate incentives

     

    90,371

     

     

    102,380

     

    Selling, general and administrative

     

    64,325

     

     

    68,096

     

    Total operating expenses

     

    154,696

     

     

    170,476

     

    Earnings from operations

     

    17,840

     

     

    24,400

     

    Other income (expense):

     

     

    Interest income

     

    2,763

     

     

    2,224

     

    Interest expense

     

    (51

    )

     

    (43

    )

    Other, net

     

    (349

    )

     

    229

     

    Other income (expense), net

     

    2,363

     

     

    2,410

     

    Earnings before income taxes

     

    20,203

     

     

    26,810

     

    Income taxes

     

    9,771

     

     

    9,518

     

    Net earnings

    $

    10,432

     

    $

    17,292

     

     

     

     

    Earnings per common share

     

     

    Basic

    $

    0.55

     

    $

    0.89

     

    Diluted

    $

    0.54

     

    $

    0.89

     

     

     

     

    Weighted average common shares outstanding

     

     

    Basic

     

    19,073

     

     

    19,321

     

    Diluted

     

    19,159

     

     

    19,427

     

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands)

    (unaudited)

     

     

    As of

    June 29,

    2024

     

    As of

    December 30,

    2023

    ASSETS

     

     

     

    Current assets

     

     

     

    Cash and cash equivalents

    $

    332,423

     

    $

    330,420

    Inventories

     

    61,832

     

     

    61,454

    Prepaid expenses and other current assets

     

    24,826

     

     

    25,872

    Total current assets

     

    419,081

     

     

    417,746

    Property and equipment, net

     

    97,686

     

     

    99,814

    Goodwill

     

    16,837

     

     

    17,102

    Intangible assets, net

     

    28,637

     

     

    29,919

    Deferred tax assets

     

    18,190

     

     

    13,284

    Other assets*

     

    50,988

     

     

    54,892

    Total assets

    $

    631,419

     

    $

    632,757

     

     

     

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

    Current liabilities

     

     

     

    Accounts payable

    $

    6,648

     

    $

    10,070

    Line of credit - short term

     

    —

     

     

    786

    Other current liabilities

     

    97,248

     

     

    107,989

    Total current liabilities

     

    103,896

     

     

    118,845

    Deferred tax liabilities

     

    4,653

     

     

    4,552

    Other long-term liabilities

     

    10,662

     

     

    12,158

     

     

     

     

    Stockholders' equity

     

    512,208

     

     

    497,202

    Total liabilities and stockholders' equity

    $

    631,419

     

    $

    632,757

    *Other assets include noncurrent inventories of $3,075 and $3,128 as of 29-Jun-24 and 30-Dec-23, respectively. Total inventories were $64,907 and $64,582 as of 29-Jun-24 and 30-Dec-23, respectively.

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    SALES BY REGION

    (in thousands)

    (unaudited)

     

     

    Quarter Ended

     

    Change from

    prior

    year

     

    Percent

    change

     

    Currency

    impact on

    sales

     

    % change

    excluding

    currency

    impact

     

    June 29, 2024

     

    July 1, 2023

     

     

     

     

    Asia Pacific

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Greater China

    $

    115,513

     

    54.3

    %

     

    $

    128,749

     

    54.1

    %

     

    $

    (13,236

    )

     

    (10.3

    %)

     

    $

    (3,085

    )

     

    (7.9

    %)

    Southeast Asia Pacific

     

    35,402

     

    16.6

    %

     

    $

    39,337

     

    16.5

    %

     

     

    (3,935

    )

     

    (10.0

    %)

     

     

    (1,221

    )

     

    (6.9

    %)

    North Asia

     

    19,710

     

    9.3

    %

     

    $

    25,529

     

    10.7

    %

     

     

    (5,819

    )

     

    (22.8

    %)

     

     

    (870

    )

     

    (19.4

    %)

    Asia Pacific Total

     

    170,625

     

    80.2

    %

     

     

    193,615

     

    81.3

    %

     

     

    (22,990

    )

     

    (11.9

    %)

     

     

    (5,176

    )

     

    (9.2

    %)

    Americas and Europe

     

    42,244

     

    19.8

    %

     

     

    44,587

     

    18.7

    %

     

     

    (2,343

    )

     

    (5.3

    %)

     

     

    (94

    )

     

    (5.0

    %)

     

    $

    212,869

     

    100.0

    %

     

    $

    238,202

     

    100.0

    %

     

    $

    (25,333

    )

     

    (10.6

    %)

     

    $

    (5,270

    )

     

    (8.4

    %)

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    ACTIVE ASSOCIATES AND ACTIVE PREFERRED CUSTOMERS BY REGION

    (unaudited)

    Active Associates by Region(1)

    (unaudited)

     

    As of

    June 29, 2024

     

    As of

    July 1, 2023

    Asia Pacific:

     

     

     

     

     

     

     

    Greater China

    68,000

     

    35.2

    %

     

    71,000

     

    34.1

    %

    Southeast Asia Pacific

    52,000

     

    27.0

    %

     

    57,000

     

    27.4

    %

    North Asia

    28,000

     

    14.5

    %

     

    33,000

     

    15.9

    %

    Asia Pacific Total

    148,000

     

    76.7

    %

     

    161,000

     

    77.4

    %

     

     

     

     

     

     

     

     

    Americas and Europe

    45,000

     

    23.3

    %

     

    47,000

     

    22.6

    %

     

    193,000

     

    100.0

    %

     

    208,000

     

    100.0

    %

     

    Active Preferred Customers by Region(2)

    (unaudited)

     

    As of

    June 29, 2024

     

    As of

    July 1, 2023

    Asia Pacific:

     

     

     

     

     

     

     

    Greater China

    182,000

     

    66.2

    %

     

    180,000

     

    64.5

    %

    Southeast Asia Pacific

    25,000

     

    9.1

    %

     

    25,000

     

    9.0

    %

    North Asia

    14,000

     

    5.1

    %

     

    18,000

     

    6.4

    %

    Asia Pacific Total

    221,000

     

    80.4

    %

     

    223,000

     

    79.9

    %

     

     

     

     

     

     

     

     

    Americas and Europe

    54,000

     

    19.6

    %

     

    56,000

     

    20.1

    %

     

    275,000

     

    100.0

    %

     

    279,000

     

    100.0

    %

    (1) Associates are independent distributors of our products who also purchase our products for their personal use. We only count as active those Associates who have purchased from us any time during the most recent three-month period, either for personal use or resale.

    (2) Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240723833865/en/

    Get the next $USNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $USNA

    DatePrice TargetRatingAnalyst
    6/23/2023Buy
    Sidoti
    7/7/2022$78.00 → $53.00Hold → Underperform
    Jefferies
    4/14/2022$86.00Neutral
    DA Davidson
    More analyst ratings

    $USNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • USANA Releases 2024 Sustainability Report

      Highlighting USANA's ongoing commitment to people, planet, and products SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- As a global leader in health and wellness, USANA is dedicated to doing its part in creating a better, healthier world. And with a commitment to positive business practices, USANA recently released its fifth annual sustainability report. This review of USANA's 2024 sustainability efforts and progress includes organizational priorities based on a comprehensive stakeholder assessment. To view the full 2024 sustainability report, please click here. "In unveiling our

      5/8/25 8:56:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • Kevin Guest Shares Transformative Success Strategies on Executive Coaching Day, May 1

      SALT LAKE CITY, May 1, 2025 /PRNewswire/ -- Kevin Guest, Executive Chairman at USANA Health Sciences (NYSE:USNA) and acclaimed author of All the Right Reasons, 12 Timeless Principles for Living a Life in Harmony, is sharing valuable insights for professionals striving to reach their peak potential. As part of Executive Coaching Day on May 1, Guest is combining decades of leadership experience with principles outlined in his bestselling book to offer actionable steps for success both in the boardroom and in life. "True success isn't just about achieving your goals; it's about l

      5/1/25 7:47:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Celavive Postbiotic Rescue Serum Selected as a Good Housekeeping 2025 Beauty Award Winner

      SALT LAKE CITY, April 28, 2025 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in cellular nutrition, announced today that its Celavive Postbiotic Rescue Serum was named as a winner in Good Housekeeping's 2025 Beauty Awards. The full list of awards can be found here. To learn more about USANA and the science behind its products, please visit USANA.com. "We're so excited that our Postbiotic Rescue Serum has been named a Good Housekeeping 2025 Beauty Award winner," said Brent Neidig, USANA's chief commercial officer. "Our product and R&D teams have put so much time

      4/28/25 7:27:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Leadership Updates

    Live Leadership Updates

    See more
    • USANA Exec. Chairman Kevin Guest Celebrates Guitar Month, Stress Awareness Month for Harmony

      SALT LAKE CITY, April 1, 2025 /PRNewswire/ -- USANA Health Sciences (NYSE:USNA) Executive Chairman Kevin Guest marks April's convergence of International Guitar Month and Stress Awareness Month, as a perfect pairing that celebrates the healing power of music for mental well-being. While music has long been heralded as a universal remedy, the guitar offers far more than just melodies. Studies, stories and specialists alike agree: playing the guitar is a proven method to reduce stress. A passionate, performing guitarist himself, Guest invites others to join the cause. "Music has

      4/1/25 7:47:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Appoints New Chief Scientific Officer

      Dr. Kathryn Armstrong brings 17 years of scientific expertise to the company SALT LAKE CITY, Jan. 22, 2025 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in cellular nutrition, is proud to announce that Dr. Kathryn Armstrong, Ph.D., will be assuming the role of chief scientific officer at the company. Kathryn has served as USANA's executive vice president of research and development since July of 2024.  Kathryn's predecessor, Dr. Rob Sinnott, announced his retirement at the end of 2024, but will continue to assist in the company's pursuit for scientific excellence as its senior scientific fellow.

      1/22/25 7:07:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Executive Chairman Kevin Guest Encourages Connections with July's "Social Wellness Month"

      SALT LAKE CITY, July 1, 2024 /PRNewswire/ -- Throughout July, Kevin Guest, executive chairman at USANA Health Sciences (NYSE:USNA), is emphasizing boosting social connections during "Social Wellness Month." Social wellness—the ability to form meaningful relationships and interact positively with others—not only enhances our emotional well-being but also significantly impacts our overall health. "Strong social connections reduce stress, improve mental health, and even extend life expectancy," said Guest. "In a world where digital interactions often replace face-to-face communic

      7/1/24 7:13:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Ding Xia

      4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

      5/21/25 2:40:18 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Director Wood Timothy E

      4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

      5/21/25 2:39:07 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Director Pelosi Peggie

      4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

      5/21/25 2:37:05 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    SEC Filings

    See more
    • SEC Form S-8 filed by USANA Health Sciences Inc.

      S-8 - USANA HEALTH SCIENCES INC (0000896264) (Filer)

      5/21/25 4:07:17 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by USANA Health Sciences Inc.

      10-Q - USANA HEALTH SCIENCES INC (0000896264) (Filer)

      5/6/25 2:42:26 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEFA14A filed by USANA Health Sciences Inc.

      DEFA14A - USANA HEALTH SCIENCES INC (0000896264) (Filer)

      5/1/25 4:44:16 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

      SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

      2/13/24 10:49:58 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

      SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

      2/13/23 11:26:45 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

      SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

      2/11/22 3:48:24 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sidoti initiated coverage on USANA

      Sidoti initiated coverage of USANA with a rating of Buy

      6/23/23 9:12:38 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA downgraded by Jefferies with a new price target

      Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously

      7/7/22 9:35:48 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • DA Davidson initiated coverage on USANA with a new price target

      DA Davidson initiated coverage of USANA with a rating of Neutral and set a new price target of $86.00

      4/14/22 7:45:27 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Financials

    Live finance-specific insights

    See more
    • USANA Health Sciences Reports First Quarter 2025 Results and Reiterates Full-Year Outlook

      USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal first quarter ended March 29, 2025. Key Financial Results First Quarter 2025 vs. First Quarter 2024 Net sales of $250 million versus $228 million, representing year-over-year growth of 10% and 12% in constant currency. Net earnings of $9.4 million versus $16.5 million. Diluted EPS of $0.49 as compared with $0.86. Adjusted diluted EPS(1) of $0.73 as compared with $0.86. Adjusted EBITDA(2) of $30 million versus $33 million. Direct selling Active Customers of 459,000 versus 494,000. Hiya Active Monthly Subscribers of 224,000. Company reiterates fiscal year 2025 outlook. Q1 2025 Financia

      4/22/25 4:05:00 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Schedules First Quarter 2025 Earnings Release and Conference Call

      USANA Health Sciences, Inc. (NYSE:USNA) today announced that first quarter 2025 results will be released after the close of market on Tuesday, April 22, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, April 23, 2025 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures hi

      4/8/25 4:05:00 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Health Sciences Reports Fourth Quarter and Full Year 2024 Results and Provides Fiscal Year 2025 Outlook

      USANA Health Sciences, Inc. (NYSE:USNA) (the "Company") today announced financial results for its fiscal fourth quarter and fiscal year ended December 28, 2024. The Company completed the acquisition of a 78.8% controlling ownership stake of Hiya Health Products, LLC ("Hiya") on December 23, 2024. Consequently, the Company's fourth quarter and fiscal year 2024 include the effect of less than a week of Hiya's operating results, which were not significant to the Company's consolidated results for the same periods. In light of the Hiya acquisition, the Company is now including metrics for Adjusted diluted EPS(1) and Adjusted EBITDA(2). Net earnings, Diluted EPS, Adjusted diluted EPS(1) and Adju

      2/25/25 4:10:00 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care